NYSE:LLYPharmaceuticals
The Bull Case For Eli Lilly (LLY) Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas
In January 2026, Illumina announced the launch of its Billion Cell Atlas alliance, naming Eli Lilly as a founding member in a program that uses CRISPR-based, large-scale genomic perturbation data and AI to map disease biology across more than 200 cell lines and hundreds of cell types.
By mid-July 2026, the Atlas had already sequenced over 350 million cells and generated several petabytes of data, positioning Lilly closer to the core of AI-driven target discovery and mechanistic insights for...